Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Nausea and Vomiting
Conditions
Chemotherapy-induced Nausea and Vomiting
Trial Timeline
Sep 14, 2015 → Feb 24, 2017
NCT ID
NCT02519842About Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist
Fosaprepitant + Placebo for fosaprepitant + Ondansetron + Dexamethasone + 5-HT3 antagonist is a phase 3 stage product being developed by Merck for Chemotherapy-induced Nausea and Vomiting. The current trial status is terminated. This product is registered under clinical trial identifier NCT02519842. Target conditions include Chemotherapy-induced Nausea and Vomiting.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-induced Nausea and Vomiting were approved
Approved (3) Terminated (3) Active (15)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02519842 | Phase 3 | Terminated |
Competing Products
20 competing products in Chemotherapy-induced Nausea and Vomiting